- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| POLARYX THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 14.09. | Polaryx Therapeutics wählt Direktoren und bestätigt Wirtschaftsprüfer auf Jahreshauptversammlung | 1 | Investing.com Deutsch | ||
| 12.09. | Polaryx Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.09. | Polaryx appoints Will Charlton as chief medical officer | 1 | Investing.com | ||
| 01.09. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer | 186 | GlobeNewswire (Europe) | Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles Appointment further strengthens clinical leadership and execution... ► Artikel lesen | |
| 13.08. | Raymond James initiates Polaryx Therapeutics stock with strong buy | 1 | Investing.com | ||
| 13.08. | Raymond James startet Coverage für Polaryx Therapeutics mit "Strong Buy" und sieht 170 % Kurspotenzial | 10 | Investing.com Deutsch | ||
| 27.07. | Lucid Capital startet Coverage für Polaryx mit Kaufempfehlung - Potenzial bei Therapie für seltene Krankheiten | 1 | Investing.com Deutsch | ||
| 27.07. | Lucid Capital initiates Polaryx stock with buy rating on rare disease therapy potential | 2 | Investing.com | ||
| 24.07. | Polaryx Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 17.07. | Polaryx Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.07. | XFRA NEW INSTRUMENTS AVAILABLE ON 03.07.2026 | 674 | Xetra Newsboard | The following instruments on XETRA do have their first trading 03.07.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.07.2026
Aktien
1 JP3100020001 Archion Corp.
2 US73110F1003... ► Artikel lesen | |
| 28.05. | Polaryx Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | Polaryx Therapeutics sichert sich 10 Millionen US-Dollar über PIPE-Finanzierung | 1 | Investing.com Deutsch | ||
| 28.05. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial | 1 | GlobeNewswire (USA) | ||
| 14.05. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards | 4 | GlobeNewswire (USA) | ||
| 21.04. | FDA grants fast track status to Polaryx's PLX-200 for three rare diseases | 2 | Investing.com | ||
| 21.04. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial | 412 | GlobeNewswire (Europe) | PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs,... ► Artikel lesen | |
| 15.04. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | 1 | GlobeNewswire (USA) | ||
| 17.03. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) | 341 | GlobeNewswire (Europe) | Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX-200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx... ► Artikel lesen | |
| 17.02. | Morning Market Movers: Polaryx Therapeutics, JIADE, ZIM Integrated Shipping Services, Masimo Corporation See Big Swings | 1.007 | AFX News | WASHINGTON (dpa-AFX) - At 7:05 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,692 | +0,11 % | Valneva mit EILMELDUNG: Jetzt könnte es für die Aktie richtig schnell gehen - Jetzt unbedingt lesen! | ||
| PALATIN TECHNOLOGIES | 9,150 | -4,49 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| OCUGEN | 0,971 | +1,15 % | Ocugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa | Ocugen will provide its investigational modifier gene therapy OCU400 through an expanded access program (EAP), with the goal of enabling the first patient to be treated for retinitis pigmentosa (RP)... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,090 | +0,46 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 16,520 | +0,36 % | Jefferies bestätigt Kaufempfehlung für Sarepta Therapeutics wegen Pipeline-Potenzial | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,568 | -3,15 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,490 | -3,11 % | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,850 | -1,44 % | RBC Capital bestätigt Rating für Ocular Therapeutix und sieht Potenzial in AMD-Therapie | ||
| VERASTEM | 6,700 | -3,90 % | Verastem präsentiert Studiendaten zu Krebstherapie auf IGC-Tagung | ||
| OXFORD NANOPORE TECHNOLOGIES | 2,574 | +9,16 % | Volta Labs launches automated library preparation solution for the Oxford Nanopore Ligation Sequencing Kit V14 | BOSTON, May 21, 2026 /PRNewswire/ -- Volta Labs, maker of the Callisto Sample Prep System, today announced the availability of its DNA Library Preparation Application for the Oxford Nanopore... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,306 | 0,00 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,240 | -2,18 % | Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns? | ||
| PALISADE BIO | 1,450 | -3,33 % | Palisade Bio, Inc.: Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026 | ||
| TVARDI THERAPEUTICS | 0,990 | -13,16 % | Tvardi meldet präklinische Daten zu STAT3-Inhibitor bei Kolitis | ||
| XBIOTECH | 1,772 | +1,61 % | XBiotech Inc.: XBiotech startet klinische Phase-II-Studie zur Bewertung von Vilamakitug bei der Behandlung der aktiven axialen Spondyloarthritis | Der IND-Antrag für die V-SPINE-Studie hat die 30-tägige FDA-Prüfung ohne klinischen Stopp durchlaufen und ebnet damit den Weg für die Aufnahme von Patienten in den USAAUSTIN, Texas, June 15, 2026 (GLOBE... ► Artikel lesen |
Das Unternehmen POLARYX THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,12 % bei einem Aktienkurs von 1,734 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLARYX THERAPEUTICS INC finden Sie auf Wallstreet Online.